World Congress on
Advances in Preventive Medicine and Public Health
THEME: "Innovating Tomorrow: The Future of Preventive Medicine and Public Health"
07-09 Jul 2025 
Prague, Czech Republic THEME: "Innovating Tomorrow: The Future of Preventive Medicine and Public Health"
07-09 Jul 2025
Prague, Czech Republic 
ZhongShan Institute for Drug Discovery, China
Title: TBA
Ding Kan is a distinguished researcher, doctoral supervisor, and project leader at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He serves as Vice Chairman of the Academic Degree Committee and Executive Vice President of the Zhongshan Institute of Pharmaceutical Innovation. His research focuses on new drug discovery for pancreatic cancer, fibrosis-related diseases, and carbohydrate-based therapeutics.
With a Ph.D. in organic chemistry from the Shanghai Institute of Materia Medica, he pursued postdoctoral research at Lund University, UC Irvine, and Harvard Medical School. He has received numerous accolades, including the CAS "Hundred Talents Program," National Outstanding Youth Science Fund, and multiple leadership awards in China.
Dr. Ding has led over 30 major national research projects and contributed extensively to the field of glycoscience, publishing over 190 papers in leading journals. He holds 76 patents and has mentored over 100 graduate students and postdocs. Currently, he plays a key role in the Human Glycome Project and serves as Deputy Editor-in-Chief of the Glycoconjugate Journal.
